IL31 and atopic eczema: Oclacitinib inhibits pathways involved in many pro-inflammatory, pro-allergic, and pruritic cytokines implicated in atopic dermatitis including interleukins (IL) 2, 4, 6, and 13 and is also involved in signaling IL-31, which has been shown to play a key role in canine pruritus [15].